Quantcast

Latest Interim analysis Stories

2014-09-23 08:30:43

Enrollment in Worldwide Trial Continues as Planned REDMOND, Wash., Sept.

2014-04-01 08:29:30

Interim results of the EFFORTLESS registry published in the European Heart Journal NATICK, Mass., April 1, 2014 /PRNewswire/ -- Real-world data on the Boston Scientific Corporation (NYSE:BSX)

2011-05-23 13:22:43

Patients with dyssynchronous yet viable ventricles are most likely to benefit from cardiac resynchronization therapy combined with defibrillation, concludes the latest analysis of the MADIT CRT trial.

2011-02-21 23:59:00

HUDDINGE, Sweden, February 22, 2011 /PRNewswire-FirstCall/ -- Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces today further positive results from the phase 2b PILLAR (C205) study of TMC435 in treatment-naive patients with hepatitis C virus (HCV) genotype-1. - TMC435 was safe and well tolerated with no clinically relevant differences in adverse events between treatment groups and standard of care...

2010-09-28 07:30:00

NATICK, Mass., Sept. 28 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed the publication of an analysis of long-term data from the MADIT II clinical trial in the current issue of Circulation.

2010-09-01 09:57:00

SYDNEY, Australia and BEDMINSTER, N.J., Sept. 1 /PRNewswire-FirstCall/ -- QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today a successful interim analysis of its final MoxDuo IR pivotal Phase 3 study required for New Drug Application (NDA) submission.


Word of the Day
dynamitard
  • A political dynamiter.
The word 'dynamitard' is related to 'dynamite', which comes from a Greek root meaning 'power' and was coined by Alfred Nobel.